Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.

H M James Hung1, Sue-Jane Wang, Robert O'Neill

  • 1Division of Biometrics I, OB/OTS/CDER, FDA, Silver Spring, Maryland 20993-0002, USA. hsienming.hung@fda.hhs.gov

Journal of Biopharmaceutical Statistics
|November 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Phase 4 Trial to Describe the Immunogenicity, Safety, and Tolerability of MenB-fHbp in Participants > 10 Years of Age With Asplenia or Complement Deficiency.

American journal of hematology·2026
Same author

Advancing Theranostics in Alzheimer Disease: FDA Approval of Amyloid-β PET Drugs for Selection of Patients for Amyloid-β-Directed Therapies and Other Labeling Updates.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Ampullary Gastrointestinal Stromal Tumor (GIST) - A Rare Culprit for Transient Biliary Obstruction.

Digestive diseases and sciences·2025
Same author

The Herald Bleed-A Fortunate Endoscopic Diagnosis of an Aorto-Duodenal Fistula Secondary to a Mycotic Aortic Aneurysm With Abscess Formation.

Clinical case reports·2025
Same author

Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial.

Human vaccines & immunotherapeutics·2025
Same author

Primary thymic mucosa-associated lymphoid tissue (MALT) lymphoma with Sjogren's syndrome and diffuse cystic lung disease: a complex respiratory presentation of a multifaceted autoimmune disease.

BMJ case reports·2024
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

Fixed sample size clinical trials use hierarchical testing for secondary endpoints. Adaptive or group-sequential designs may compromise type I error control, impacting pharmaceutical product labeling.

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Pharmaceutical Research

Background:

  • Clinical trials often use fixed sample sizes to test primary efficacy endpoints.
  • Secondary endpoints are tested hierarchically after primary endpoint significance for product labeling.
  • Conventional hierarchical testing ensures strong type I error control in fixed designs.

Purpose of the Study:

  • To evaluate the impact of adaptive and group-sequential designs on type I error control for secondary endpoints.
  • To assess potential violations of the closure principle in modern clinical trial designs.
  • To ensure robust statistical validity for pharmaceutical product claims based on secondary endpoints.

Main Methods:

  • Analysis of statistical testing strategies in clinical trials.

Related Experiment Videos

  • Comparison of conventional fixed designs with group-sequential and adaptive designs.
  • Examination of the closed testing principle and type I error control.

    • Main Results:

    • Group-sequential and adaptive designs can violate the closure principle.
    • Conventional hierarchical testing may not maintain strong type I error control in adaptive trials.
    • Potential for inflated type I error rates when testing secondary endpoints in flexible trial designs.

    Conclusions:

    • Adaptive and group-sequential designs require careful consideration of statistical testing procedures.
    • Standard hierarchical testing may be insufficient for controlling type I error in flexible clinical trial designs.
    • Ensuring statistical rigor is crucial for valid secondary endpoint claims in pharmaceutical labeling.